Heard Capital discloses 9.4% activist stake in Anterix

A regulatory 13D filing on Anterix states: “The Reporting Persons purchased the Shares based on the Reporting Persons’ belief that the Shares represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable. On May 28, 2024, Mr. Heard submitted his consent to the Issuer to be named as a director of the Board, and on July 3, 2024, the Issuer filed its definitive proxy statement in connection with its 2024 Annual Meeting of Stockholders, naming Mr. Heard as a director candidate of the Issuer to be elected to the Board at the Annual Meeting. If Mr. Heard is not elected by the Issuer’s stockholders at the Annual Meeting, the Reporting Persons may nonetheless work constructively with members of the Issuer’s management team and Board in an effort to continue enhancing and maximizing stockholder value. As a result of Mr. Heard being nominated as a director candidate for election to the Board, the Reporting Persons are converting the beneficial ownership filing on Schedule 13G to a filing on Schedule 13D.”